ArticleCytoJournal2026
Upregulation of itchy E3 ubiquitin protein ligase contributes to endometrial cancer through promoting forkhead box P1 degradation.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Endometrial cancer (EC) is one of the most prevalent cancers affecting the female reproductive system and originates from the uterine epithelium, posing a significant health burden to postmenopausal women. As an E3 ubiquitin ligase, itchy E3 ubiquitin protein ligase (ITCH) plays a key role in the progression of multiple kinds of solid cancers, but its function in EC remains unclear. This work aims to explore the roles of ITCH during the carcinogenesis of EC. Material and Methods: The messenger RNA (mRNA) level of ITCH in 47 paired EC tissue and adjacent non-tumor controls was examined by quantitative polymerase chain reaction. The protein level of ITCH in formalin-fixed paraffin-embedded EC tissue and adjacent non-tumor controls from 47 patients with EC was detected by immunohistochemistry. Data on the RNA levels of ITCH and forkhead box P1 (FOXP1), along with prognostic information for 541 patients with EC, were obtained from the Human Protein Atlas database. A chromatin immunoprecipitation assay was employed to investigate the interaction between FOXP1 and the promoter of the KRAS proto-oncogene GTPase (KRAS). Results: Both ITCH mRNA and protein levels are upregulated in EC tissues. Patients with lower ITCH expression exhibit prolonged overall survival. In EC tissue samples, ITCH protein level negatively correlates with the FOXP1 protein level. ITCH interacts with FOXP1 in EC cells and promotes its ubiquitination and subsequent degradation. FOXP1 inhibits KRAS expression in EC cells by binding to its promoter region. ITCH overexpression suppresses the FOXP1-KRAS axis, leading to increased proliferation and reduced apoptosis of EC cells. Conclusion: ITCH functions as an oncogene in EC, promoting carcinogenesis by inducing FOXP1 degradation and upregulating KRAS expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.